Health-care companies rose as one obesity-drug maker surged following a promising clinical trial.
Viking Therapeutics shares jumped by roughly one-third after a study showed that patients taking its weight-loss injection could keep weight off even when switching to less frequent doses.
Danish Ozempic maker Novo Nordisk wallowed around recent lows, amid concerns about intensifying competition in the popular weight-loss category.
Swiss drug maker Roche said an obesity drug candidate met the main objectives of a midstage clinical trial by helping patients reduce their blood glucose and body weight.
A task force commissioned by Vice President JD Vance will remove as many as 750,000 enrollments from the Affordable Care Act's public exchanges, citing enrollee ineligibility and fraud.
Maze Therapeutics rallied after rival Vertex Pharmaceuticals reported positive study results for its kidney disease drug, stoking optimism about demand for kidney products.